Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Leukemia, Promyelocytic, Acute 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × vadastuximab talirine × Clear all
NCT02326584 2018-05-09

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

Seagen Inc.

Phase 1 Completed
116 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01902329 2018-01-05

A Safety Study of SGN-CD33A in AML Patients

Seagen Inc.

Phase 1 Completed
195 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡